カテゴリー別アーカイブ: 未分類

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Long-acting Inhaled Medicines (LAIM) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Long-acting Inhaled Medicines (LAIM) market, including market size, share, demand, industry development status, and forecasts for the next few years.

For patients with chronic respiratory diseases, the burden of managing conditions like asthma and chronic obstructive pulmonary disease (COPD) extends beyond symptom control to include complex medication regimens that can compromise adherence and therapeutic outcomes. Short-acting therapies, while effective for acute relief, require multiple daily doses, increasing the risk of missed doses and inconsistent disease management. Long-acting inhaled medicines (LAIM) address this challenge through molecular engineering and advanced pharmaceutical technologies that achieve prolonged therapeutic effects with reduced dosing frequency. This class encompasses long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), as well as innovative formulations incorporating controlled-release mechanisms, mucoadhesive systems, and large porous particle designs that extend the pharmacological effect post-inhalation. The global market for long-acting inhaled medicines, valued at US$2,812 million in 2025, is projected to reach US$3,706 million by 2032, growing at a compound annual growth rate (CAGR) of 4.1%. With global average pricing around US$12.68 per unit and total sales reaching approximately 213 million units in 2024, the sector reflects steady growth driven by the rising prevalence of respiratory diseases, the shift toward once-daily dosing regimens, and continuous innovation in inhalation formulation technology.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098557/long-acting-inhaled-medicines–laim

Market Segmentation and Technology Architecture

The long-acting inhaled medicine market is structured by drug class and therapeutic application, each with distinct formulation strategies:

• By Type (Drug Class): The market segments into Long-acting Muscarinic Antagonists (LAMAs) and Long-acting Beta-Agonists (LABAs). LAMAs provide sustained bronchodilation through M3 receptor blockade, with once-daily dosing and proven efficacy in reducing COPD exacerbations. LABAs act through beta-2 adrenergic receptor stimulation, available in both once-daily (indacaterol, olodaterol) and twice-daily (formoterol, salmeterol) formulations. The combination of LAMAs and LABAs in fixed-dose products represents the fastest-growing segment, offering complementary bronchodilation through dual mechanisms. Emerging formulation technologies, including controlled-release and mucoadhesive systems, further extend the duration of action beyond traditional molecule pharmacology.
• By Application (Disease Indication): The market segments into Asthma, COPD, and Others. COPD currently accounts for the largest market share, with LAIM recommended as first-line maintenance therapy for moderate-to-severe disease. Asthma applications represent a significant segment, with LABAs used exclusively in combination with inhaled corticosteroids (ICS) for persistent asthma. The “Others” category includes off-label applications and emerging indications.

Competitive Landscape and Recent Industry Developments

The competitive landscape features a concentration of global pharmaceutical leaders with respiratory expertise. Key players profiled include Boehringer Ingelheim, Teva Pharmaceutical, Novartis, The Menarini Group, Covis Pharma, Zentiva, Alfasigma, Gebro-Pharma, Kohl Medical, Cipla, GSK, Viatris, LEK-AM, AstraZeneca, Chiesi Farmaceutici, Orion Corporation, Polpharma, Adamed Group, STADA Arzneimittel, Zhejiang Xianjun Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, and Nanchang Helioeast Technology. A significant trend observed over the past six months is the accelerated development of novel long-acting formulation technologies. Manufacturers are investing in large porous particle (LPP) designs that achieve extended lung retention, and mucoadhesive systems that prolong drug residence time in the airways, potentially extending dosing intervals beyond 24 hours.

Additionally, the market has witnessed notable advancement in fixed-dose combination products that combine multiple mechanisms of action with complementary pharmacokinetic profiles, enabling once-daily administration of dual bronchodilator and triple therapy regimens.

Exclusive Industry Perspective: Divergent Formulation Strategies for Extended Duration of Action

A critical analytical distinction emerging within the inhalation therapeutics market is the divergence between formulation strategies for extending duration of action beyond the inherent pharmacokinetics of the drug molecule. In molecular engineering approaches, the emphasis is on developing novel chemical entities with intrinsically long receptor binding kinetics. Drugs like tiotropium (LAMA) and indacaterol (LABA) achieve 24-hour duration through high receptor affinity and slow dissociation rates. According to clinical data, these inherently long-acting molecules achieve consistent bronchodilation with once-daily dosing, forming the foundation of current LAIM portfolios.

In formulation-based approaches, requirements shift toward advanced particle engineering and drug delivery systems that extend lung retention and control drug release. Large porous particle (LPP) formulations achieve extended residence time through reduced macrophage uptake, while mucoadhesive systems utilize polymers that bind to airway mucus, prolonging contact time with target tissues. Recent case studies from novel LAIM development demonstrate that formulation-based approaches can extend the duration of action of shorter-acting molecules to once-daily or even once-weekly dosing, expanding the therapeutic potential of existing drug classes.

Technical Innovation and Advanced Delivery Systems

Despite the maturity of inhalation therapy, the respiratory drug delivery industry continues to advance through particle engineering and controlled-release technology. Large porous particle (LPP) design has become a key differentiator, with particles >5 microns achieving reduced macrophage clearance while maintaining deep lung deposition through low density and aerodynamic properties optimized for inhalation.

Another evolving technical frontier is the development of dry powder formulations with enhanced aerosolization efficiency. Advanced carrier systems and engineered particles achieve fine particle fractions exceeding 50%, compared to 20-30% for conventional formulations, enabling lower nominal doses and improved efficacy.

Market Dynamics and Growth Drivers

The respiratory therapeutics sector is benefiting from several structural trends supporting LAIM adoption. The rising global prevalence of COPD and asthma, affecting over 500 million people worldwide, expands the patient population requiring maintenance therapy. The shift toward once-daily and simplified dosing regimens improves patient adherence, a critical factor in chronic disease management. Innovation in formulation technology enables extended duration of action and novel combination products. Additionally, generic market expansion increases access to LAIM therapy in price-sensitive markets.

Conclusion

The global long-acting inhaled medicines market represents the convergence of molecular pharmacology and advanced formulation science, delivering sustained therapeutic benefit with simplified dosing regimens for patients with chronic respiratory diseases. As the prevalence of COPD and asthma continues to rise, as patient adherence becomes increasingly central to disease management, and as formulation technologies enable further extensions of duration of action, the demand for innovative LAIM products will continue to grow. The forthcoming QYResearch report provides comprehensive segmentation analysis, regional market sizing, technology assessments, and strategic profiles of key manufacturers, equipping stakeholders with actionable intelligence to navigate this essential respiratory therapeutics market.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Long-acting Bronchodilators – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Long-acting Bronchodilators market, including market size, share, demand, industry development status, and forecasts for the next few years.

For patients with chronic obstructive pulmonary disease (COPD) and asthma, the consistent management of airway obstruction is fundamental to maintaining respiratory function, preventing exacerbations, and sustaining quality of life. Short-acting bronchodilators, while effective for acute symptom relief, require multiple daily doses and fail to provide the sustained airway protection needed for chronic disease management. Long-acting bronchodilators address this challenge by providing maintenance medications that deliver 12 to 24 hours of bronchodilation through once-daily or twice-daily dosing. This class encompasses long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs), which work through complementary mechanisms to relax airway smooth muscles, improve airflow, and reduce the risk of acute exacerbations. The global market for long-acting bronchodilators, valued at US$2,778 million in 2025, is projected to reach US$3,683 million by 2032, growing at a compound annual growth rate (CAGR) of 4.2%. With global average pricing around US$12.02 per unit and total sales reaching approximately 221 million units in 2024, the sector reflects steady growth driven by rising COPD prevalence, the central role of long-acting bronchodilators in maintenance therapy, and the expansion of fixed-dose combination products.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098549/long-acting-bronchodilators

Market Segmentation and Product Architecture

The long-acting bronchodilator market is structured by drug class and therapeutic application, each with distinct mechanisms of action:

• By Type (Drug Class): The market segments into Long-acting Muscarinic Antagonists (LAMAs) and Long-acting Beta-Agonists (LABAs). LAMAs currently account for a significant market share, providing sustained bronchodilation through blockade of M3 muscarinic receptors in airway smooth muscles, with once-daily dosing and proven efficacy in reducing COPD exacerbations. LABAs represent a complementary segment, acting through beta-2 adrenergic receptor stimulation to relax airway smooth muscle, available in both once-daily (indacaterol, olodaterol) and twice-daily (formoterol, salmeterol) formulations. The combination of LAMAs and LABAs in fixed-dose products represents the fastest-growing segment, offering complementary bronchodilation through dual mechanisms.
• By Application (Disease Indication): The market segments into Asthma, COPD, and Others. COPD currently accounts for the largest market share, with long-acting bronchodilators recommended as first-line maintenance therapy for patients with moderate-to-severe disease. Asthma applications represent a significant segment, with LABAs used in combination with inhaled corticosteroids (ICS) for patients with persistent asthma not adequately controlled on ICS alone. The “Others” category includes off-label applications and rare respiratory conditions.

Competitive Landscape and Recent Industry Developments

The competitive landscape features a concentration of global pharmaceutical leaders with respiratory expertise. Key players profiled include Boehringer Ingelheim, Teva Pharmaceutical, Novartis, The Menarini Group, Covis Pharma, Zentiva, Alfasigma, Gebro-Pharma, Kohl Medical, Cipla, GSK, Viatris, LEK-AM, AstraZeneca, Chiesi Farmaceutici, Orion Corporation, Polpharma, Adamed Group, STADA Arzneimittel, Zhejiang Xianjun Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, and Nanchang Helioeast Technology. A significant trend observed over the past six months is the accelerated adoption of fixed-dose combination (FDC) products combining LAMAs and LABAs, and triple combinations with inhaled corticosteroids (ICS). Dual bronchodilator therapy (LAMA/LABA) has become standard of care for patients with moderate-to-severe COPD, while triple therapy (ICS/LABA/LAMA) is preferred for patients with frequent exacerbations or elevated eosinophil counts.

Additionally, the market has witnessed notable innovation in delivery device technology. Next-generation dry powder and soft mist inhalers incorporate dose counters, breath-actuation mechanisms, and digital connectivity that enhance adherence and provide feedback to patients and healthcare providers.

Exclusive Industry Perspective: Divergent Requirements in LAMA vs. LABA Monotherapy

A critical analytical distinction emerging within the respiratory therapeutics market is the divergence between LAMA and LABA monotherapy applications. In LAMA monotherapy, the emphasis is on sustained bronchodilation, exacerbation reduction, and appropriate patient selection for COPD. LAMAs are preferred for patients with moderate COPD, those with less frequent exacerbations, and patients who cannot tolerate beta-agonists. According to clinical guidelines, LAMA monotherapy reduces COPD exacerbations by 15-25% compared to placebo, with improvements in lung function sustained over years of use.

In LABA monotherapy, applications focus on bronchodilation with rapid onset and, in asthma, combination with ICS. LABAs are rarely used as monotherapy in asthma due to safety concerns regarding increased exacerbation risk; they are always prescribed with ICS. In COPD, LABAs offer effective bronchodilation with a different adverse effect profile, providing options for patients who may not tolerate anticholinergic agents.

Technical Innovation and Formulation Science

Despite the maturity of bronchodilator technology, the respiratory drug delivery industry continues to advance through formulation optimization and device innovation. Delivery efficiency has become a key differentiator, with next-generation dry powder and soft mist inhalers achieving lung deposition rates of 30-40% compared to 15-25% for older devices, improving efficacy at lower nominal doses.

Another evolving technical frontier is the development of digital health integration. Advanced delivery systems combining once-daily bronchodilators with electronic adherence monitoring enable remote tracking of medication use, providing early warning of treatment gaps that could precede exacerbations and supporting value-based care models.

Market Dynamics and Growth Drivers

The COPD therapeutics sector is benefiting from several structural trends supporting long-acting bronchodilator adoption. The rising global prevalence of COPD and asthma, affecting over 500 million people worldwide, expands the patient population requiring maintenance bronchodilator therapy. The shift toward fixed-dose combination products improves treatment adherence and therapeutic outcomes. Generic market expansion increases access to bronchodilator therapy in price-sensitive markets. Additionally, the development of once-daily formulations simplifies treatment regimens, supporting adherence in chronic disease management.

Conclusion

The global long-acting bronchodilators market represents a foundational component of respiratory disease management, providing sustained bronchodilation, exacerbation reduction, and improved quality of life for millions of patients with COPD and asthma. As disease prevalence continues to rise, as combination therapies become standard of care, and as device and formulation innovations improve patient experience and outcomes, the demand for high-quality long-acting bronchodilator products will continue to grow. The forthcoming QYResearch report provides comprehensive segmentation analysis, regional market sizing, technology assessments, and strategic profiles of key manufacturers, equipping stakeholders with actionable intelligence to navigate this essential respiratory therapeutics market.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Long-acting Anticholinergic Bronchodilators – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Long-acting Anticholinergic Bronchodilators market, including market size, share, demand, industry development status, and forecasts for the next few years.

For patients with chronic obstructive pulmonary disease (COPD) and asthma, the consistent management of airway obstruction is fundamental to maintaining respiratory function, preventing exacerbations, and sustaining quality of life. Short-acting bronchodilators, while effective for acute symptom relief, require multiple daily doses and fail to provide the sustained airway protection needed for chronic disease management. Long-acting anticholinergic bronchodilators (LAMAs) address this challenge by blocking muscarinic receptors in airway smooth muscles, providing prolonged bronchodilation that reduces bronchoconstriction and improves lung function with once-daily dosing. These maintenance medications—including tiotropium, glycopyrrolate, aclidinium, and umeclidinium—represent the cornerstone of COPD maintenance therapy, reducing exacerbation frequency and enhancing patient adherence through convenient administration. The global market for long-acting anticholinergic bronchodilators, valued at US$2,245 million in 2025, is projected to reach US$2,900 million by 2032, growing at a compound annual growth rate (CAGR) of 3.8%. With global average pricing around US$11.23 per unit and total sales reaching approximately 192 million units in 2024, the sector reflects steady growth driven by rising COPD prevalence, the central role of LAMAs in maintenance therapy, and the expansion of fixed-dose combination products.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098528/long-acting-anticholinergic-bronchodilators

Market Segmentation and Product Architecture

The LAMA market is structured around active ingredient and therapeutic application, each with distinct pharmacokinetic and clinical profiles:

• By Type (Active Ingredient): The market segments into Aclidinium, Glycopyrrolate, Tiotropium, Umeclidinium, and Others. Tiotropium currently accounts for the largest market share, as the first-in-class LAMA with extensive clinical experience, proven efficacy in reducing COPD exacerbations, and established safety profile across multiple delivery devices. Glycopyrrolate represents a significant segment, available in both dry powder inhaler and nebulized formulations, with rapid onset and sustained duration. Aclidinium and umeclidinium maintain presence in combination products and as alternatives for patients with specific device preferences or tolerability considerations.
• By Application (Disease Indication): The market segments into Asthma, COPD, and Others. COPD currently accounts for the dominant market share, with LAMAs recommended as first-line maintenance therapy for patients with moderate-to-severe COPD, particularly those with frequent exacerbations or persistent symptoms. Asthma applications represent a smaller but growing segment, with LAMAs used in combination with inhaled corticosteroids (ICS) for patients with severe asthma inadequately controlled on ICS/long-acting beta-agonist (LABA) therapy.

Competitive Landscape and Recent Industry Developments

The competitive landscape features a concentration of global pharmaceutical leaders with respiratory expertise. Key players profiled include Boehringer Ingelheim, Teva Pharmaceutical, Novartis, The Menarini Group, Covis Pharma, Zentiva, Alfasigma, Gebro-Pharma, Kohl Medical, Cipla, GSK, Zhejiang Xianjun Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, and Nanchang Helioeast Technology. A significant trend observed over the past six months is the accelerated adoption of fixed-dose combination (FDC) products combining LAMAs with long-acting beta-agonists (LABAs) and inhaled corticosteroids (ICS). Triple combination therapies (ICS/LABA/LAMA) have become standard of care for patients with frequent exacerbations, driving sustained market growth.

Additionally, the market has witnessed notable innovation in delivery device technology. Next-generation LAMA inhalers incorporate dose counters, breath-actuation mechanisms, and patient feedback systems that enhance adherence—particularly important for once-daily maintenance therapies where consistent use is critical to preventing exacerbations.

Exclusive Industry Perspective: Divergent Requirements in LAMA Monotherapy vs. Combination Therapy

A critical analytical distinction emerging within the COPD therapeutics market is the divergence between LAMA monotherapy applications versus combination therapy strategies. In LAMA monotherapy applications, the emphasis is on sustained bronchodilation, exacerbation reduction, and appropriate patient selection. LAMA monotherapy is recommended for patients with moderate COPD, those with less frequent exacerbations, and patients who cannot tolerate or have contraindications to LABAs. According to clinical guidelines, LAMA monotherapy reduces COPD exacerbations by 15-25% compared to placebo, with improvements in lung function and quality of life sustained over years of use.

In combination therapy applications, requirements shift toward dual bronchodilation (LAMA/LABA) or triple therapy (ICS/LABA/LAMA) for patients with more severe disease, frequent exacerbations, or elevated eosinophil counts. Recent clinical trial data demonstrates that triple therapy reduces exacerbation rates by 20-30% compared to dual therapy in appropriately selected patients, establishing combination products as standard of care for high-risk COPD populations.

Technical Innovation and Formulation Science

Despite the maturity of LAMA technology, the respiratory drug delivery industry continues to advance through formulation optimization and device innovation. Delivery efficiency has become a key differentiator, with next-generation dry powder inhalers achieving lung deposition rates of 30-40% compared to 15-25% for older devices, improving efficacy at lower nominal doses.

Another evolving technical frontier is the development of digital health integration. Advanced delivery systems combining once-daily LAMAs with electronic adherence monitoring enable remote tracking of medication use, providing early warning of treatment gaps that could precede exacerbations and supporting value-based care models.

Market Dynamics and Growth Drivers

The COPD therapeutics sector is benefiting from several structural trends supporting LAMA adoption. The rising global prevalence of COPD, affecting over 300 million people worldwide, expands the patient population requiring maintenance bronchodilator therapy. The shift toward fixed-dose combination products improves treatment adherence and therapeutic outcomes. Generic market expansion increases access to LAMA therapy in price-sensitive markets. Additionally, the development of once-daily formulations simplifies treatment regimens, supporting adherence in chronic disease management.

Conclusion

The global long-acting anticholinergic bronchodilators market represents a foundational component of COPD maintenance therapy, providing sustained bronchodilation, exacerbation reduction, and improved quality of life for millions of patients worldwide. As COPD prevalence continues to rise, as combination therapies become standard of care, and as device and formulation innovations improve patient experience and outcomes, the demand for high-quality LAMA products will continue to grow. The forthcoming QYResearch report provides comprehensive segmentation analysis, regional market sizing, technology assessments, and strategic profiles of key manufacturers, equipping stakeholders with actionable intelligence to navigate this essential respiratory therapeutics market.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Enteric Premixed Film Coating Powder – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Enteric Premixed Film Coating Powder market, including market size, share, demand, industry development status, and forecasts for the next few years.

For pharmaceutical manufacturers, formulation scientists, and drug developers, the protection of active pharmaceutical ingredients (APIs) from gastric degradation and the precise delivery of drugs to the intestinal tract are critical to therapeutic efficacy and patient outcomes. Traditional immediate-release formulations, while suitable for many drugs, fail to protect acid-labile compounds from gastric acid degradation, leading to reduced bioavailability, variable absorption, and gastrointestinal irritation. Enteric premixed film coating powder addresses these challenges by providing composite powder or pre-blended mixtures specifically designed for enteric coating of tablets and granules. Composed of enteric polymers, excipients, plasticizers, and functional additives, these formulations protect drugs from degradation in the stomach and enable release at specific sites in the intestine—improving drug stability, targeted efficacy, and patient compliance. The global market for enteric premixed film coating powder, valued at US$79 million in 2025, is projected to reach US$119 million by 2032, growing at a compound annual growth rate (CAGR) of 6.1%. With global production reaching approximately 2,830 tons in 2024 and average pricing around US$26,500 per ton, the sector reflects steady growth driven by increasing demand for oral solid dosage forms, the expansion of acid-labile drug development, and the growing complexity of formulation requirements.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098449/enteric-premixed-film-coating-powder

Market Segmentation and Product Architecture

The enteric coating market is structured around release profile and application domain, each with distinct formulation requirements:

• By Type (Release Profile): The market segments into Standard Enteric Type, Controlled-Release Enteric Type, and Targeted Enteric Type. Standard Enteric Type currently accounts for the largest market share, providing pH-dependent dissolution (typically at pH >5.5-6.0) to protect drugs from gastric acid and enable intestinal release. These formulations are widely used for acid-labile drugs, gastro-irritant compounds, and delayed-release applications. Controlled-Release Enteric Type represents a growing segment, combining enteric protection with sustained release kinetics for drugs requiring extended intestinal absorption or once-daily dosing regimens. Targeted Enteric Type serves specialized applications requiring site-specific release in the colon or specific intestinal segments, enabling localized therapy for inflammatory bowel disease and colonic drug delivery.
• By Application (Formulation Type): The market segments into Western Medicine and Traditional Chinese Medicine applications. Western Medicine currently accounts for the largest market share, driven by the extensive use of enteric coating for acid-labile drugs, proton pump inhibitors, and gastro-irritant compounds in conventional pharmaceutical development. Traditional Chinese Medicine (TCM) applications represent a growing segment, with enteric coating used to protect sensitive herbal extracts from gastric degradation and to deliver traditional formulations with enhanced bioavailability.

Competitive Landscape and Recent Industry Developments

The competitive landscape features a mix of global excipient leaders and specialized coating technology providers. Key players profiled include Colorcon, Kerry, Alsiano, Seppic, Imerys, Tianjing ILE, Yuekang Pharmaceutical Group, Lianyungang Wantai Pharm Excipients Tech, Lianyungang Huanyu Bitumen, Shanghai Inno-polymer Pharmaceutical Technology, and Lianyungang Hengyang Pharmaceutical. A significant trend observed over the past six months is the accelerated development of high-performance enteric polymers with enhanced stability and processability. Next-generation enteric coating formulations incorporate advanced polymer blends that achieve robust acid resistance with faster dissolution at intestinal pH, improving formulation reliability and reducing coating process variability.

Additionally, the market has witnessed notable innovation in solvent-free and aqueous-based coating systems. Water-based enteric coating formulations have gained market share over solvent-based systems, driven by environmental considerations, reduced safety risks, and simplified manufacturing processes.

Exclusive Industry Perspective: Divergent Requirements in Western vs. Traditional Medicine Applications

A critical analytical distinction emerging within the pharmaceutical excipient market is the divergence between requirements for Western pharmaceutical formulations versus Traditional Chinese Medicine (TCM) applications. In Western pharmaceutical applications, the emphasis is on precise pH-dependent release, robust acid resistance, and consistent dissolution profiles. Western drug developers require enteric coating systems validated to USP/EP specifications, with well-characterized performance across manufacturing scale-up. According to recent formulation data, standard enteric coatings achieve acid resistance exceeding 95% in gastric fluid (pH 1.2) with complete dissolution within 30-60 minutes at intestinal pH, providing predictable release profiles for regulatory submission.

In Traditional Chinese Medicine applications, requirements shift toward compatibility with complex herbal extracts, taste masking, and preservation of traditional product identity. TCM formulations often contain multiple herbal extracts with varying physicochemical properties, requiring enteric coating systems that achieve consistent coverage without compromising the integrity of traditional preparations. Recent case studies from TCM manufacturers demonstrate that enteric-coated traditional formulations have improved bioavailability of sensitive herbal compounds by 30-50% while maintaining the historical identity of the original preparation.

Technical Innovation and Formulation Science

Despite the maturity of enteric coating technology, the pharmaceutical excipient industry continues to advance through polymer science and coating process innovation. Functional polymer development has become a key differentiator, with manufacturers developing novel enteric polymers with enhanced moisture resistance, improved processability, and reduced coating weight requirements—enabling thinner coatings with equivalent protective performance.

Another evolving technical frontier is the integration of enteric coating with other functional film properties. Multi-functional coating systems combining enteric protection with taste masking, moisture barrier, or color customization enable formulation simplification and enhanced product differentiation.

Market Dynamics and Growth Drivers

The pharmaceutical development sector is benefiting from several structural trends supporting enteric coating powder adoption. The expansion of acid-labile drug development, including proton pump inhibitors, peptides, and biologics, drives demand for enteric protection. The growth of oral solid dosage forms, representing the preferred route of administration for patient convenience, sustains demand for coating excipients. The focus on targeted drug delivery for gastrointestinal diseases creates new applications for specialized enteric coating systems. Additionally, the modernization of Traditional Chinese Medicine formulations, with emphasis on bioavailability and patient compliance, expands the addressable market.

Conclusion

The global enteric premixed film coating powder market represents a critical enabling technology for oral solid dosage formulations, providing the protection and targeted release essential for acid-labile drugs, gastro-irritant compounds, and specialized delivery applications. As pharmaceutical development continues to expand, as the complexity of formulation requirements increases, and as the focus on bioavailability and patient compliance intensifies, the demand for high-quality enteric coating solutions will continue to grow. The forthcoming QYResearch report provides comprehensive segmentation analysis, regional market sizing, technology assessments, and strategic profiles of key manufacturers, equipping stakeholders with actionable intelligence to navigate this essential pharmaceutical excipient market.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Medicinal Stevioside – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Medicinal Stevioside market, including market size, share, demand, industry development status, and forecasts for the next few years.

For pharmaceutical developers, nutraceutical formulators, and healthcare professionals, the rising global burden of metabolic disorders—including diabetes, obesity, and hypertension—has intensified the search for natural therapeutic agents that combine safety with efficacy. Conventional synthetic sweeteners, while effective for caloric reduction, often raise concerns about long-term safety and fail to provide additional health benefits. Medicinal stevioside addresses this gap by providing a group of natural high-intensity sweeteners extracted from the leaves of Stevia rebaudiana Bertoni, composed primarily of diterpene glycosides such as stevioside and rebaudiosides. Beyond its established role as a non-caloric sweetener, medicinal stevioside has demonstrated pharmacological activities including glucose regulation, antihypertensive effects, anti-inflammatory, and antioxidant properties—positioning it as a promising therapeutic agent for diabetes, obesity, and cardiovascular disorders. The global market for medicinal stevioside, valued at US$95 million in 2025, is projected to reach US$143 million by 2032, growing at a compound annual growth rate (CAGR) of 6.1%. With global sales reaching approximately 2,140 tons in 2024 and average pricing around US$41,500 per ton, the sector reflects accelerating growth driven by increasing prevalence of metabolic diseases, consumer preference for natural ingredients, and expanding applications in pharmaceutical and nutraceutical formulations.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098444/medicinal-stevioside

Market Segmentation and Product Architecture

The medicinal stevioside market is structured around purity grade and application domain, each with distinct quality requirements:

• By Type (Purity Grade): The market segments into Purity 95%-98%, Purity 98%-99%, and Purity Above 99%. Purity grades above 99% currently account for the fastest-growing segment, driven by pharmaceutical applications requiring the highest purity for drug formulation, clinical research, and regulatory compliance. These high-purity stevioside products minimize undesirable aftertaste characteristics and ensure consistent pharmacological activity. The 98%-99% purity segment serves premium nutraceutical applications, while the 95%-98% segment addresses cost-sensitive formulations and research-grade applications.
• By Application (End-Market): The market segments into Pharmaceuticals, Health Supplements, and Others. Pharmaceuticals currently account for the largest and fastest-growing market share, driven by increasing research into stevioside’s therapeutic potential for diabetes, hypertension, and metabolic syndrome. Health Supplements represent a significant and growing segment, with stevioside incorporated into products targeting blood sugar management, weight control, and cardiovascular health. The “Others” category includes functional foods and beverages.

Competitive Landscape and Recent Industry Developments

The competitive landscape features a mix of global stevia ingredient leaders and specialized pharmaceutical-grade manufacturers. Key players profiled include PureCircle, Cargill, Sunrise Nutrachem Group, Crodarom, Merisant, Shandong Huaxian Haosen Biotechnology, Shandong Sugar Baby Biotechnology, Jilin Aodong Biotechnology, Shandong Jiake Biotechnology, Shandong Haigen Biotechnology, Hunan Erkang Pharmaceutical, Sichuan Bolley Heng Pharmaceutical, and BONTAC Biotechnology. A significant trend observed over the past six months is the accelerated development of pharmaceutical-grade steviol glycosides with enhanced purity profiles and standardized pharmacological activity. Manufacturers have invested in advanced purification technologies that achieve consistent purity levels (>99%) while preserving the bioactive properties of individual steviol glycosides.

Additionally, the market has witnessed notable advancement in clinical research validating stevioside’s therapeutic applications. Recent clinical studies have demonstrated stevioside’s efficacy in reducing systolic blood pressure in hypertensive patients and improving insulin sensitivity in type 2 diabetes, supporting expanded pharmaceutical applications.

Exclusive Industry Perspective: Divergent Requirements in Pharmaceutical vs. Nutraceutical Applications

A critical analytical distinction emerging within the natural therapeutic market is the divergence between requirements for pharmaceutical-grade stevioside versus nutraceutical applications. In pharmaceutical applications, the emphasis is on consistent purity, batch-to-batch reproducibility, and regulatory compliance. Pharmaceutical-grade stevioside must meet stringent quality specifications, with documented pharmacological activity, stability data, and compliance with Good Manufacturing Practice (GMP) standards. According to recent clinical development data, pharmaceutical applications require stevioside purity exceeding 98% with detailed characterization of individual steviol glycoside profiles to ensure consistent therapeutic effects.

In nutraceutical applications, requirements shift toward natural positioning, cost-effectiveness, and consumer appeal. Nutraceutical formulations prioritize clean label positioning, with stevioside serving as a natural sweetener and functional ingredient in dietary supplements targeting metabolic health. Recent case studies from supplement manufacturers demonstrate that stevioside-enriched formulations have achieved 15-20% market share growth in the blood sugar management category, driven by consumer preference for natural, plant-based ingredients.

Technical Innovation and Therapeutic Development

Despite the established use of stevia as a sweetener, the pharmaceutical ingredient industry continues to advance through formulation science and clinical research. Bioavailability enhancement has become a key differentiator, with manufacturers developing delivery systems that improve the absorption and therapeutic efficacy of steviol glycosides for systemic applications.

Another evolving technical frontier is the development of steviol glycoside combinations that optimize therapeutic outcomes. Formulations combining stevioside with other natural compounds (berberine, chromium, cinnamon) for metabolic health applications are gaining traction in nutraceutical markets.

Market Dynamics and Growth Drivers

The natural therapeutics sector is benefiting from several structural trends supporting medicinal stevioside adoption. The global increase in diabetes and obesity prevalence, affecting over 500 million people worldwide, creates sustained demand for natural blood sugar management solutions. Consumer preference for plant-based, natural ingredients over synthetic alternatives drives adoption in pharmaceutical and nutraceutical formulations. The growing body of clinical evidence supporting stevioside’s therapeutic benefits expands addressable applications. Additionally, regulatory acceptance of steviol glycosides as safe ingredients across major markets facilitates commercial development.

Conclusion

The global medicinal stevioside market represents a dynamic and growing segment within natural therapeutics, offering unique combination of non-caloric sweetness and pharmacological activity for metabolic health applications. As diabetes and obesity prevalence continues to rise, as clinical evidence for stevioside’s therapeutic benefits accumulates, and as consumer demand for natural ingredients intensifies, the demand for high-quality medicinal stevioside will continue to accelerate. The forthcoming QYResearch report provides comprehensive segmentation analysis, regional market sizing, technology assessments, and strategic profiles of key manufacturers, equipping stakeholders with actionable intelligence to navigate this evolving natural therapeutics market.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Short-acting Bronchodilators – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Short-acting Bronchodilators market, including market size, share, demand, industry development status, and forecasts for the next few years.

For patients with asthma and chronic obstructive pulmonary disease (COPD), the ability to rapidly relieve acute airway constriction is fundamental to preventing severe exacerbations, avoiding emergency department visits, and maintaining quality of life. While long-acting maintenance therapies reduce underlying inflammation and prevent symptoms, acute episodes—triggered by allergens, exercise, infection, or environmental factors—require immediate intervention to restore normal breathing. Short-acting bronchodilators (SABAs and SAMAs) address this critical need by providing rescue medications that rapidly relax airway smooth muscle, opening constricted bronchial passages during acute asthma attacks and COPD exacerbations. These essential medications—including albuterol, levalbuterol, and ipratropium—are delivered via metered-dose inhalers and nebulizers, forming the cornerstone of emergency respiratory care and patient self-management. The global market for short-acting bronchodilators, valued at US$4,489 million in 2025, is projected to reach US$5,932 million by 2032, growing at a compound annual growth rate (CAGR) of 4.1%. With global average pricing around US$19.60 per unit and total sales reaching approximately 220 million units in 2024, the sector reflects steady growth driven by rising respiratory disease prevalence, increasing emergency care utilization, and the essential role of rescue medications in asthma and COPD management.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098340/short-acting-bronchodilators

Market Segmentation and Product Architecture

The rescue bronchodilator market is structured around active ingredient and therapeutic application, each with distinct mechanisms of action:

• By Type (Active Ingredient): The market segments into Albuterol, Levalbuterol, Ipratropium, and Others. Albuterol currently accounts for the largest market share, serving as the most widely prescribed short-acting beta-agonist (SABA) globally, with established efficacy, safety profile, and availability in multiple generic formulations. Levalbuterol, the purified (R)-isomer of albuterol, offers similar bronchodilation with potentially reduced side effects, maintaining a premium segment presence. Ipratropium, a short-acting muscarinic antagonist (SAMA), provides bronchodilation through a complementary mechanism, often used in COPD exacerbations and in combination with albuterol for enhanced effect.
• By Application (Disease Indication): The market segments into Asthma, COPD, and Others. Asthma currently accounts for the largest market share, with SABAs recommended as first-line rescue therapy for all patients with asthma, regardless of severity. COPD represents a significant and growing segment, with SABAs and SAMAs used for symptom relief in COPD patients experiencing acute exacerbations. The “Others” category includes exercise-induced bronchoconstriction and acute bronchospasm from other causes.

Competitive Landscape and Recent Industry Developments

The competitive landscape features a mix of global pharmaceutical leaders and generic manufacturers with respiratory expertise. Key players profiled include Boehringer Ingelheim, GSK, Teva Pharmaceutical, Prasco Laboratories, Cipla, Lupin Laboratories, Laboratorio Aldo-Union, Polpharma, Jewim Pharmaceutical, Heilongjiang Fulekang Pharmaceutical, Shanghai Pharmaceuticals, Lunan Better Pharmaceutical, and China Resources Double Crane Pharmaceutical. A significant trend observed over the past six months is the accelerated development of hydrofluoroalkane (HFA)-free propellant systems in response to environmental concerns. The transition from HFA-134a and HFA-227 propellants to low-global warming potential (low-GWP) alternatives is reshaping formulation development, with major manufacturers investing in reformulation programs to meet environmental regulations while maintaining product performance.

Additionally, the market has witnessed notable innovation in breath-actuated and dose-counting devices. Next-generation rescue inhalers incorporate built-in dose counters that improve adherence tracking and reduce the risk of running out of medication during acute episodes—a critical safety feature for patients who may require rescue therapy infrequently.

Exclusive Industry Perspective: Divergent Requirements in Asthma vs. COPD Rescue Applications

A critical analytical distinction emerging within the respiratory rescue market is the divergence between requirements for asthma management versus COPD exacerbation applications. In asthma management, the emphasis is on rapid onset, consistent bronchodilation, and pediatric suitability. Albuterol remains the standard for asthma rescue, with onset of action within 5-10 minutes and duration of 4-6 hours sufficient for most acute episodes. According to recent clinical guidelines, SABA-only rescue remains appropriate for mild intermittent asthma, while step-up therapy recommendations emphasize anti-inflammatory maintenance with continued rescue access.

In COPD exacerbation management, requirements shift toward combination bronchodilation, higher dosing, and integration with maintenance therapy. COPD exacerbations often require both beta-agonist and anticholinergic bronchodilation (albuterol plus ipratropium) for optimal effect, with some patients requiring nebulized therapy for adequate delivery. Recent case studies from COPD management programs demonstrate that combination short-acting bronchodilator therapy reduces hospital admission rates by 20-25% when administered early during exacerbation onset.

Technical Innovation and Supply Chain Dynamics

Despite the maturity of rescue bronchodilator technology, the respiratory drug delivery industry continues to advance through propellant development and device innovation. Propellant transition represents the most significant industry transformation, with manufacturers reformulating products to use low-GWP propellants while maintaining consistent aerosol characteristics, dose uniformity, and stability.

Another evolving technical frontier is the integration of digital health capabilities into rescue inhalers. Connected inhalers with dose tracking, geolocation for environmental triggers, and integration with mobile health applications enable patients to monitor rescue medication use, providing early warning of worsening control and facilitating timely intervention.

Market Dynamics and Growth Drivers

The respiratory therapeutics sector is benefiting from several structural trends supporting short-acting bronchodilator adoption. The rising global prevalence of asthma and COPD, affecting over 500 million people worldwide, expands the patient population requiring rescue medication access. The essential role of rescue therapy in asthma and COPD management ensures sustained demand regardless of maintenance therapy advances. Generic market expansion increases access to affordable rescue medications in price-sensitive markets. Additionally, the focus on patient self-management and action plans reinforces the importance of reliable rescue medication availability.

Conclusion

The global short-acting bronchodilators market represents a foundational component of respiratory emergency care and patient self-management, providing essential relief for millions of patients experiencing acute bronchospasm from asthma and COPD. As respiratory disease prevalence continues to rise, as environmental regulations reshape propellant development, and as digital health integration enhances patient monitoring and adherence, the demand for reliable, accessible rescue bronchodilator products will continue to grow. The forthcoming QYResearch report provides comprehensive segmentation analysis, regional market sizing, technology assessments, and strategic profiles of key manufacturers, equipping stakeholders with actionable intelligence to navigate this essential respiratory rescue market.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Ciclesonide Inhalation Aerosol – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ciclesonide Inhalation Aerosol market, including market size, share, demand, industry development status, and forecasts for the next few years.

For respiratory physicians, asthma patients, and healthcare providers, the effective control of airway inflammation is fundamental to preventing asthma exacerbations and maintaining long-term respiratory health. Traditional inhaled corticosteroids, while effective, often present trade-offs between local efficacy and systemic bioavailability, with patient adherence challenged by dosing frequency and administration complexity. Ciclesonide inhalation aerosol addresses these challenges by providing a prescription medication specifically designed for the control and prevention of asthma in adults and children aged 12 years and older. As a prodrug that is activated in the lungs to its active metabolite (desisobutyryl-ciclesonide), ciclesonide delivers fine particles deep into the airways, providing targeted anti-inflammatory action with minimal systemic exposure. This unique mechanism enables once-daily dosing for many patients while maintaining effective inflammation control. The global market for ciclesonide inhalation aerosol, valued at US$171 million in 2025, is projected to reach US$219 million by 2032, growing at a compound annual growth rate (CAGR) of 3.7%. With global average pricing around US$24.60 per unit and total sales reaching approximately 6.71 million units in 2024, the sector reflects steady growth driven by the rising prevalence of asthma, the unique advantages of ciclesonide formulation, and continued focus on adherence-friendly respiratory therapies.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098295/ciclesonide-inhalation-aerosol

Market Segmentation and Product Architecture

The ciclesonide MDI market is structured around dosage strength and therapeutic application, each with distinct patient population targeting:

• By Type (Dosage Strength): The market segments into 80mcg and 100mcg metered-dose inhalation aerosols. The 80mcg dosage currently accounts for a significant market share, serving as the standard maintenance dose for patients with mild-to-moderate persistent asthma. This strength provides effective inflammation control with once-daily administration, supporting adherence through simplified regimens. The 100mcg dosage serves patients requiring higher-dose corticosteroid therapy, including those with more severe persistent asthma or inadequate control on lower doses. Dosage selection is typically guided by disease severity, prior treatment history, and individual patient response.
• By Application (Disease Indication): The market segments into Asthma, COPD, and Others. Asthma currently accounts for the largest market share, with ciclesonide approved for asthma maintenance therapy across the United States, Europe, and other major markets. COPD applications represent an emerging segment, with some formulations studied for chronic bronchitis and COPD management, though use remains off-label in many regions. The “Others” category includes rare respiratory conditions where anti-inflammatory corticosteroid therapy is indicated.

Competitive Landscape and Recent Industry Developments

The competitive landscape features a concentration of global and regional pharmaceutical manufacturers with expertise in respiratory drug development. Key players profiled include Covis Pharma, Zentiva, AstraZeneca, Zhejiang Xianjun Pharmaceutical, and Anhui Wellman Pharmaceutical. A significant trend observed over the past six months is the accelerated development of generic ciclesonide formulations following patent expirations in key markets. Generic entry has expanded patient access and created price competition, with multiple manufacturers now producing ciclesonide MDIs for global markets.

Additionally, the market has witnessed notable innovation in inhalation device design. Next-generation ciclesonide MDIs incorporate improved dose counters, breath-actuation mechanisms, and integrated patient feedback systems that enhance adherence and provide accurate dosing information, addressing the challenge of suboptimal adherence in chronic respiratory disease management.

Exclusive Industry Perspective: Divergent Requirements in Ciclesonide vs. Traditional Corticosteroid Formulations

A critical analytical distinction emerging within the inhaled corticosteroid market is the divergence between ciclesonide’s unique pharmacologic properties versus traditional inhaled corticosteroid formulations. In ciclesonide formulations, the emphasis is on lung activation, once-daily dosing, and reduced systemic exposure. As a prodrug activated by esterases in the lung, ciclesonide achieves high local anti-inflammatory activity with minimal systemic bioavailability, reducing the risk of systemic corticosteroid side effects including growth suppression in children, bone density loss, and adrenal suppression. According to clinical trial data, ciclesonide demonstrates comparable efficacy to twice-daily inhaled corticosteroids with significantly lower cortisol suppression, supporting its use in patients requiring long-term corticosteroid therapy.

In traditional corticosteroid formulations, the emphasis has historically been on potent airway anti-inflammatory activity with acceptable systemic profiles. While effective, traditional inhaled corticosteroids often require twice-daily dosing and carry higher risk of systemic effects, particularly at higher doses. Recent case studies from asthma management programs demonstrate that transition to once-daily ciclesonide has improved patient adherence by 15-25% compared to twice-daily regimens, with corresponding reductions in exacerbation rates and healthcare utilization.

Technical Innovation and Formulation Science

Despite the maturity of MDI technology, the respiratory drug delivery industry continues to advance through formulation science and device integration. Particle size optimization remains critical for ciclesonide delivery, with formulations designed to generate fine particles (<5 microns) that reach the small airways and alveoli where inflammation in asthma is concentrated.

Another evolving technical frontier is the integration of electronic adherence monitoring. Ciclesonide MDIs with digital dose tracking enable remote monitoring of patient adherence, providing healthcare providers with actionable data to identify patients at risk of poor control and intervene proactively.

Market Dynamics and Growth Drivers

The respiratory therapeutics sector is benefiting from several structural trends supporting ciclesonide adoption. The rising global prevalence of asthma, affecting over 260 million people worldwide, expands the patient population requiring maintenance corticosteroid therapy. The focus on patient adherence and simplified dosing regimens favors once-daily medications. The availability of generic formulations expands access to ciclesonide therapy in price-sensitive markets. Additionally, the shift toward personalized asthma management, with treatment selection based on patient characteristics and preferences, creates opportunities for differentiated corticosteroid formulations.

Conclusion

The global ciclesonide inhalation aerosol market represents a specialized yet essential segment within respiratory therapeutics, offering unique advantages in lung-targeted corticosteroid delivery, once-daily dosing, and reduced systemic exposure. As asthma prevalence continues to rise, as patient adherence becomes increasingly central to disease management, and as the transition to generic formulations expands access, the market for ciclesonide MDIs will continue to grow. The forthcoming QYResearch report provides comprehensive segmentation analysis, regional market sizing, technology assessments, and strategic profiles of key manufacturers, equipping stakeholders with actionable intelligence to navigate this specialized respiratory drug delivery market.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp